One of the neuropathological lesions characteristic of Alzheimer disease (AD) is the cerebral accumulation of the amyloid ␤-peptide (A␤). Although numerous studies have demonstrated that A␤ spontaneously forms amyloid in vitro, the molecular events underlying A␤ amyloid formation in vivo are less well understood. Immunohistochemical studies have shown that other proteins colocalize with A␤ in amyloid deposits in brain. The identity of one of these proteins, AMY, has so far remained elusive; therefore we attempted to purify AMY. The AMY protein was found to co-purify with A␤ in insoluble fractions from human AD brain, and was absent in brains from control subjects. AMY immunoreactivity was primarily restricted to a 50-kDa and 100-kDa protein species. Interestingly, the chromatographic and immunological profile of AMY resembled the recently identified amyloid-associated protein CLAC, derived from a transmembrane collagen-like precursor, CLAC-P. Antibodies against AMY recognized CLAC-P expressed in mammalian cells. In addition, side-by-side comparisons of AD brain sections and extracts, using antibodies against both AMY and CLAC, respectively, resulted in almost identical staining patterns. Therefore, we conclude that the AMY immunoreactivity seen in association with amyloid in AD brain is due to the presence of the CLAC protein.
INTRODUCTION
Deposition of the amyloid ␤-peptide (A␤) into senile plaques is one of the distinguishing neuropathological features of Alzheimer disease (AD) (1) . Plaque deposition occurs both in the brain parenchyma and cerebral blood vessels. An impressive body of biochemical and genetic evidence links the A␤ peptide to disease pathogenesis; therefore, events leading to the deposition of the 40-42 residue A␤ peptide in brain tissue provide possible targets for disease intervention (2) .
The A␤ peptide is an internal proteolytic fragment of the ␤-amyloid precursor protein (␤APP) (3) . After initial cleavage by the protease BACE, liberating the N terminus of A␤, a second processing event occurs in the transmembrane domain of ␤APP generating the soluble A␤ peptide. In certain families, specific mutations near or inside the A␤ domain of ␤APP or in the presenilin genes co-segregate with AD (4) . Many of these mutations share a common APP processing phenotype: they specifically increase production of the A␤42 variant (5) . This longer A␤42 form aggregates more rapidly than the more common A␤40 form in vitro (6) , and has been shown to be the initially deposited species in AD brain (7) . ␤APP processing has been studied in many different cell types in vitro, and A␤ generation from ␤APP is not restricted to cells of a neuronal origin. In addition, A␤ can be detected as an apparent soluble peptide in human plasma and cerebrospinal fluid (8) . The question remains why pathological A␤ deposition is exclusively confined to the brain.
Although A␤ is the major component of the plaques, a host of other proteins have been colocalized with A␤ in AD brain (9) , most notably ␣ 1 -antichymotrypsin (10), complement factor C1q (11) , and apolipoprotein E (apoE) (12) . Studies in transgenic mice support a role for apoE and ␣ 1 -antichymotrypsin in quantitatively determining plaque abundance (13, 14) and studies in vitro indicate a direct interaction between A␤ and apoE (15) and ␣ 1 -antichymotrypsin (16) , respectively. Neither apoE nor ␣ 1 -antichymotrypsin are brain-specific proteins. Thus, there may exist yet unidentified proteins in A␤ deposits that affect plaque genesis and/or turnover and compartment specificity.
One candidate for a molecule in this brain-specific arena could be the still unidentified AMY protein. In a screen for antibodies generated against fractions enriched in paired helical filaments, the other characteristic pathological feature of AD, a subset of the antibodies labeled A␤ plaque-like structures (17) . This so-called AMY immunoreactivity was shown to colocalize with A␤ in plaques both in AD and Down syndrome brains (17, 18 neuropsychiatric disorders. In aged control subjects, where compacted fibrillary plaques could be seen, AMY immunoreactivity was also present (18) . Although preliminary biochemical characterization suggests that the AMY antigen is extractable from brain tissue (17) , the identity remains elusive.
Here we describe attempts at purifying the AMY antigen from human AD brain using the antibodies described above. We show that AMY immunoreactivity copurifies with A␤ in SDS-resistant fractions and that no AMY is present in these fractions from control cases. The 50-kDa and 100-kDa AMY immunoreactive protein species were further purified by size-exclusion and reversed phase liquid chromatography. Although different strategies were employed we did not obtain protein or peptide sequences unambiguously identifying AMY. We therefore chose an alternative strategy based on the similarity in immunoreactivity between AMY and the collagen-like Alzheimer amyloid plaque component (CLAC), a recently identified AD amyloid-associated protein derived from a novel transmembrane collagen, CLAC-P (19) . We show that AMY antibodies recognize CLAC-P expressed in cells and that the biochemical and immunohistochemical labeling pattern for antibodies against AMY and CLAC are indistinguishable. Thus, we propose that the AMY protein is identical to CLAC.
MATERIALS AND METHODS

Subject Groups
Autopsied brain tissue (frontal cortex) from AD patients and controls was used for the initial biochemical characterization of AMY and for the comparative immunohistochemical studies. The specifics of the cases are given in the appropriate figure legends.
Preparation of Amyloid-Enriched Material from Human Brain
Cortical gray matter from AD and control brains were homogenized in 5 volumes of buffer containing 1% SDS in phosphate-buffered saline (PBS), pH 7.4, and centrifuged at 100,000 ϫ g for 30 min. The resulting pellet was re-extracted in the same buffer and the procedure was repeated at least 3 times until a white pellet surrounded by a brown halo was obtained (20) . The final pellet was further extracted in 70% formic acid (FA) by brief sonication, before a second high-speed centrifugation at 150,000 ϫ g for 1 h was performed. The extracted supernatant was passed through layers of gauze to remove coarse debris and lyophilized by vacuum centrifugation. The dried pellet was delipidated and analyzed by immunoblotting and liquid chromatography.
Liquid Chromatography
The delipidated amyloid-enriched pellet was resuspended in 70% FA, sonicated briefly, and loaded onto a Superose 12 HR 10/30 column (Amersham Biosciences, Uppsala, Sweden). The column was developed with 70% FA at a flow rate of 0.4 ml/ min. The effluent was monitored at 280 nm and 0.4-ml fractions were collected. Small-scale size-exclusion chromatography (SEC) was also performed on a Superose 12 PC 3.2/30 column (Amersham Biosciences) at a flow rate of 50 l/min (100-l fractions collected). A small aliquot of each fraction was analyzed by immunoblotting for AMY immunoreactivity. Fractions containing AMY were pooled, dried by vacuum centrifugation, and resuspended in 6 M guanidine-HCl or 70% FA, and further separated by reversed phase liquid chromatography (RPLC) on an AceC 8 column (2.1 ϫ 150 mm; Advanced Chromatography Technology, Aberdeen, Scotland). Proteins were eluted with a linear gradient of 10% to 60% acetonitrile in 0.1% trifluoroacetic acid at a flow rate of 0.2 ml/min, and fractions were collected every 2 min. AMY immunoreactive RPLC fractions were pooled and subjected to digests using a panel of different proteases. Peptides were separated by RPLC and analyzed by Edman sequencing.
Immunoblot Analysis
Brain samples were resuspended in 9 M of urea, 100 mM Tris-HCl, pH 10.5, and then mixed with sample buffer and subjected to SDS-PAGE. Immunoblot analysis was performed using the AMY monoclonal antibodies, AMY155 and AMY117, which were initially raised to immunogens extracted from paired helical filament-rich extracts of AD neocortex (17) . A monoclonal antibody against CLAC (9D2) was also used (19) . Myc/His-tagged CLAC-P expressed in CHO cells was identified using a myc antibody (Invitrogen, Life Technologies, Carlsbad, CA).
Cloning of CLAC-P and cDNA Constructs
The precursor protein CLAC-P was cloned from a human brain cDNA library (QUICK-Clone cDNA, BD Bioscience Clontech, Palo Alto, CA). Using 1 ng of the library as a template, touch down PCR was performed using the upstream primer 5Ј-ATGCTGCTGAAGAAGCACGC-3Ј and the downstream primer 5Ј-TCACTTTTGCCAACAGCCAG-3Ј, based on the recently discovered CLAC-P nucleotide sequence (Accession No. AF293341). Amplified CLAC-P was subcloned into a pCR 2.1-TOPO TA cloning vector (Invitrogen, Life Technologies) and further cloned into a mammalian expression vector pcDNA3.1/myc-His (Invitrogen, Life Technologies) containing a C-terminal myc/His-tag. Truncated variants of CLAC-P were generated by insertion of stop codons using the Quick Change Site-Directed Mutagenesis Kit according to the manufacturer's protocol (Stratagene, La Jolla, CA). The resulting cDNA constructs were sequenced for verification.
Cell Culture and Transfections
CHOPro5 cells were maintained in alpha MEM medium supplemented with 10% fetal bovine serum, penicillin, and streptomycin. Transfections were carried out using Lipofectamine PLUS (Invitrogen, Life Technologies) according to the supplier's instructions. Twenty-four hours after transfection, cell lysate was prepared and analyzed by immunoblotting using the monoclonal antibodies, AMY155, AMY117, and a myc antibody. In order to detect secreted CLAC lacking the transmembrane domain, media were collected 48 h after transfection, cleared from debris by centrifugation at 16,000 ϫ g for 10 min
Immunohistochemistry
The immunohistochemical procedures used here have been described (17) . Briefly, tissue blocks from 2 AD cases (described in Subject groups) were fixed in 70% ethanol containing 150 mM NaCl, and 6-M-thick consecutive sections from each case were immunostained with monoclonal antibodies AMY155 or 9D2. Antibody binding was visualized with the avidin-biotin-peroxidase complex kit (Vector Laboratories, Burlingame, CA) and 3,3Ј diaminobenzidine/H 2 0 2 (Sigma, St. Louis, MO) as substrate.
RESULTS
We have previously shown that deposited A␤ and amyloid-associated apoE are found in very insoluble fractions from human AD brain homogenates (21) . Since the immunohistochemical profile of AMY in AD brain resembled apoE and suggested a true association with A␤ amyloid, we initially searched for AMY in SDS-resistant fractions from AD brain. Briefly, brain tissue was repeatedly homogenized in a buffer containing 1% SDS and centrifuged at 100,000 ϫ g for 1 h. The resulting SDS-insoluble pellet was re-extracted in 70% FA, lyophilized, and subjected to immunoblot analysis. As shown previously, A␤ can be found in the FA extract both in the form of an apparent monomer and in higher molecular weight aggregates ( Fig. 1A) (21) . Probing the membranes with monoclonal AMY antibodies 155 (Fig. 1B) and 117 (not shown) demonstrated that no AMY-immunoreactive bands could be detected in FA extracts from control subjects, whereas prominent AMY bands could be seen in extracts from AD brain. Shown are 2 representative cases from each group, out of several different brains analyzed. No A␤ could be found in the FA fraction from the control brains (data not shown). The AMY immunoreactivity was exclusively confined to the SDS-resistant FA extracts (Fig. 1C) , indicating that AMY, similar to A␤, acquires insoluble features in AD brain. It was found that the AMY155 antibody generally resulted in better and more consistent signals from the immunoblots; therefore, this antibody was used throughout most of the remainder of this study. As seen from Figure 1B and C, the AMY155 antibody primarily labeled a 50-kDa and 100-kDa protein species. Several AD brains were analyzed and the presence of the 50-and 100-kDa protein bands varied between the different brains (data not shown). The 50-kDa AMY-immunoreactive protein was often seen in the absence of the larger AMY protein bands, suggesting that the 100-kDa protein band represents an SDS-and FA-stable dimer of the 50-kDa protein species.
A chromatographic protocol with the aim to purify AMY to homogeneity from AD brain was devised. We have previously used size-exclusion chromatography (SEC) in 70% FA to partially purify amyloid-associated components from AD brain (21) , therefore, we also chose this paradigm for the initial AMY purification step. An AMY-containing FA extract was applied to a Superose 12 column using 70% FA as mobile phase at a flow rate of 50 l/min. Fractions (100 l) were collected and aliquots of these analyzed by SDS-PAGE and immunoblotting ( Fig. 2A-C) . The AMY immunoreactivity could be found in fractions close to the void volume of the column (Fig. 2B) , whereas monomeric and oligomeric A␤ eluted in lower molecular weight fractions (Fig. 2C) . On longer exposures, an A␤ immunoreactive smear could also be seen in fractions 1 and 2 (data not shown), partly corresponding to A␤ bound to apoE (21) .
The SEC-fractionated material was further purified by RPLC. AMY-immunoreactive fractions from the SEC were pooled and FA removed by vacuum centrifugation. The dried AMY-immunoreactive material was resuspended in 6 M guanidine-HCl and resolved on a C8 RPLC column (Fig. 2D, E) . AMY primarily elutes between 32% and 37% acetonitrile under the conditions used, although the material is not resolved into distinct peaks. Several different chromatographic conditions were tested using silica-based columns or a polystyrene column with basic pH elution buffers; however, none of these alternate conditions resulted in clearly resolved AMY-immunoreactive peaks (data not shown). We also observed that the yield of AMY decreased dramatically when the material was separated by RPLC, limiting the amount of partially purified material available for further analysis.
AMY-immunoreactive RPLC fractions were pooled and subjected to parallel digests using various endoproteases. Very little material appeared as peptide peaks in the subsequent RPLC separations, suggesting inefficient digestion, and none of the digests generated legible peptide sequences. In parallel experiments, proteins were transferred to PVDF membranes for direct N-terminal Edman sequencing. Many of the excised Coomassiestained bands co-migrating with the 50-kDa AMY-immunoreactive band appeared to contain N-terminally blocked proteins, since the cycle yield usually was very low and no sequences could be discerned. The failure to obtain sequences prompted us to devise an alternative approach to identify AMY.
Very recently, the purification and identification of a novel amyloid-associated protein in AD brain was reported (19) . This protein, termed CLAC, appears to be a fragment of a larger type II precursor protein CLAC-P/ Col XXV, which is exclusively expressed in neurons and binds to A␤ in vitro. The precursor protein of CLAC is composed of 3 collagen-like domains (COL1-3), which are separated by 4 noncollagenous domains (NC1-4) Immunoblot analysis using the AMY155 antibody of FA extracts isolated from frontal cortex of 2 AD and 2 control brains. The AD brains met CERAD criteria for definite AD. AMY immunoreactivity is exclusively detected in AD brains as a 50-kDa and 100-kDa protein species (arrowheads). The 2 AD cases were aged 65 and 83 years, respectively, and the 2 control cases were aged 64 and 86 years, respectively. The nondemented controls did not show any signs of AD pathology in the frontal cortex, as determined by routine Bielschowsky silver and immunohistochemical staining. C: AMY immunoreactivity is only confined to the SDS-resistant FA extracts highly enriched in A␤. (Fig. 3) , and is partially homologous to the nonfibrillar collagen type XIII. The similarities between the immunohistochemical profiles of CLAC and AMY in AD brain are striking. In addition, the CLAC antibody used for screening the progression of the purification was raised against semi-purified amyloid from AD brain, partly resembling the approach used for generating the AMY antibodies. These data prompted us to clone and express CLAC-P/Col XXV.
CLAC-P was cloned from an adult whole brain human cDNA library. We obtained a novel 580 residue splice variant with a partially truncated C-terminal (Fig. 3) . This splice variant was subcloned into a mammalian expression vector containing a C-terminal myc/His-tag. CHO (COL1-3) , and the transmembrane domain (TM, residue 39-55) as a dark gray box. The domains are represented in relation to their size and the amino acid residue numbers indicated above correspond to the domains of CLAC-P/Col XXV (Accession No. AF293341). The novel splice variant of CLAC-P cloned in this study, consisting of 580 residues, is more extensively truncated at the C-terminal compared to previously reported splice variants of CLAC-P/Col XXV. The amino acid residues that are lacking in the splice variant are indicated by bars and correspond to residue numbers 141-146, 326-340 and 589-640, respectively. Fig. 4 . CLAC-P expressed in CHO cells is recognized by the AMY155 antibody. CHO cells were transiently transfected with CLAC-P fused with a C-terminal myc/His-tag. Cell lysate was prepared from CLAC-P and mock-transfected cells. Conditioned media were collected 48 h after transfection, passed over a HiTrap chelating column, and fractions were eluted with 300 mM imidazole. Cell lysates and prepared media were subjected to SDS-PAGE followed by immunoblot analysis using a myc antibody (A) and the AMY155 antibody (B). ← phase at a flow rate of 50 l/min. Absorbance was monitored at 280 nm and fractions of 100 l were collected. B: AMY immunoreactivity from the SEC-separation in (A). Aliquots from each fraction were resolved on a 7.5% SDS-PAGE gel and immunoblotted using the AMY155 antibody. C: Fractions from (A) were resolved on a 10% to 20% tricine gel followed by immunoblotting using the 6E10 antibody. Note that AMY and A␤ does not co-elute under the conditions used. D: Separation of AMY-containing SEC-fractions by reversed phase chromatography. AMY-immunoreactive fractions from a large scale SEC fractionation (data not shown) were pooled and loaded onto an AceC8 column (2.1 mm ϫ 150 mm). Proteins were eluted with a linear gradient of 10-60% acetonitrile (ACN) in 0.1% trifluoroacetic acid, (dotted line) at a flow rate of 0.2 ml/min. Absorbance was monitored at 280 nm and fractions of 0.4 ml were collected. E: Fractions were pooled (0.8 ml) and aliquots from these were resolved on a 7.5% SDS-PAGE gel followed by immunoblotting with AMY155 antibody. The 50-kDa and 100-kDa AMY protein species were found in fractions 9 through 12, corresponding to an ACN concentration of ϳ35%.
cells were transiently transfected with this construct and expression of protein was assayed by immunoblotting of cell lysates. Using a myc antibody, tagged CLAC-P could be detected in cell lysates as a band migrating with an apparent molecular weight of ϳ80 kDa (Fig. 4A, lane 2) . The AMY155 antibody also labeled this band (Fig. 4B , lane 2), suggesting that the CLAC-P protein is identical to AMY. CLAC-P has previously been shown to undergo furin-like processing in mammalian cells, leading to secretion of a ϳ70-kDa protein fragment lacking the transmembrane domain (19) . No myc or AMY antibody-reactive proteins were detected in the cultured medium unless myc/His-tagged CLAC-P was enriched for by affinity purification. After this treatment, both antibodies labeled a faster migrating species (Fig. 4A and B, lane  3) . The AMY117 antibody, which detects both the 50-and 100-kDa AMY species in SDS-insoluble FA fractions from AD brain, also recognized the CLAC-P variant cloned in this study. Similar to AMY155, labeling could only be seen after cultured media was enriched for the ϳ70-kDa secreted ectodomain of CLAC-P by affinity purification (data not shown).
To further establish the indistinguishable characteristics between AMY and CLAC, SDS-insoluble extracts from AD brain were divided in 2 equal aliquots, where one aliquot was probed with AMY155 and the other aliquot probed with the CLAC antibody 9D2 (19 . Top: SDS-PAGE analysis of the SDS-insoluble fraction prepared from AD brain followed by side-by-side immunoblot using the AMY155 and 9D2 antibodies, respectively. Tissue from frontal cortex was obtained from an AD case aged 83 years. Bottom: Immunohistochemical comparison between the AMY155 and 9D2 antibodies on consecutive AD brain sections. Ethanol-fixed sections from mid-frontal cortex of 2 AD cases aged 71 (panels I and II) and 91 (panels III and IV) were used. Note the overall similarity in staining for AMY155 (panels I and III) and 9D2 (panels II and IV). Some of the specific structures labeled by both antibodies are indicated with open arrowheads. Scale bar: 100 m.
in Figure 5A , both AMY155 and 9D2 label identical protein species on immunoblots. Both antibodies were also used on ethanol-fixed consecutive sections from midfrontal cortex of 2 AD cases (Fig. 5B) . Both antibodies labeled the same plaque-like structures (compare panels I and II and panels III and IV, respectively). It was consistently found that the immunoreactivity was weaker for 9D2 than for AMY155, an effect that may be due to 6 . Characterization of the epitope of the AMY155 antibody. C-terminally truncated CLAC-P constructs were generated by insertion of stop codons using site-directed mutagenesis. A: Stop codons were introduced after residue 450 (450⌬), 423 (423⌬), 390 (390⌬), 358 (358⌬), and 310 (310⌬). B: Cell lysates from transfections using the different constructs were subjected to SDS-PAGE analysis followed by immunoblotting using the AMY155 antibody. The epitope for AMY155 is contained within the COL2 domain between residues 311-358. The amino acid numbering corresponds to CLAC-P/Col XXV (Accession No. AF293341).
location of the epitope for the respective antibody (see below). Taken together, the comparable appearances between AMY and CLAC in cells, brain extracts, and histological sections strongly suggest that the AMY and CLAC proteins are identical.
Finally, we wanted to determine the epitope for the AMY155 antibody in order to obtain additional information of the AMY fragment deposited in brain. To this end, we analyzed lysates from cells transfected with Cterminally truncated CLAC-P constructs (Fig. 6A) . Stop codons were introduced after residue 310 (310⌬), 358 (358⌬), 390 (390⌬), 423 (423⌬), and after residue 450 (450⌬). The AMY155 antibody reacted with expressed 450⌬, 423⌬, 390⌬, and 358⌬ but not with 310⌬ (Fig.  6B) , suggesting that the epitope is contained within residues 311-358 in collagen domain 2 (COL2). Interestingly, the amino acid sequence is 100% identical between humans and rodents in this 48-residue region. The epitope for 9D2 is believed to be located at a more N-terminal site within the NC2 domain of CLAC-P (19) .
DISCUSSION
Here we show that the AD amyloid-associated protein AMY (17) is identical to the previously purified CLAC protein (19) . We base this conclusion on the following observations: 1) the biochemical characteristics, such as solubility and chromatographic elution pattern, are interchangeable between CLAC and AMY; 2) CLAC-P expressed in mammalian cells is recognized by antibodies directed against AMY; and, finally, 3) antibodies toward AMY and CLAC label identical protein species in SDSinsoluble brain extracts and the immunohistochemical profile is interchangeable between the antibodies. For clarity, the 2 proteins will be referred to by their respective designations throughout the discussion.
The antibodies against AMY were raised against immunogens present in particulate fractions from human AD brain (17) . The immunohistochemical data obtained using these antibodies suggests that the colocalization of AMY with A␤ deposits is extensive in AD, both in sporadic and in familial cases (18, 22, 23 AMY immunoreactivity seen in AD brain seems to be restricted to the neuritic A␤ plaques present in the parenchyma, whereas A␤ amyloid deposits present in cerebral vessels remained refractory towards staining (17, 18) . Notably, the antibodies used to follow the purification of CLAC from brain were also raised against particulate fractions from AD brain (19) . One line of evidence for the identity between AMY and CLAC was obtained from the biochemical fractionation studies performed in this study. AMY is exclusively present in SDS-resistant fractions from human AD brain and AMY from brain appears to migrate both as a 50-kDa and a 100-kDa protein species (Fig. 1B) . Both of these properties have also recently been attributed to CLAC (19) and were confirmed in this study where the use of both AMY and CLAC antibodies resulted in an identical protein labeling on immunoblots (Fig. 5A) . The identity between AMY and CLAC was also further corroborated by immunohistochemical means (Fig. 5B) . Finally, transfection of a cDNA encoding CLAC-P in mammalian cells results in the production of AMY-immunoreactive protein species (Fig. 4) .
The splice variant of CLAC-P isolated in this study appears as a ϳ80-kDa cellular protein and as a ϳ70-kDa secreted soluble protein when analyzed with an AMY antibody. The secreted variant is most probably resulting from furin processing of the membrane-bound precursor, as previously shown (19) . These 2 protein entities are not represented in the SDS-insoluble fraction from AD brain. Our attempts to obtain an N-terminal sequence from partially purified AMY indicated that the N terminus was post-translationally modified (i.e. blocked). The N terminus of CLAC deposited in AD brain undergoes pyroglutamate modification, as previously shown (19) and may have relevance to the N-terminal block that preclude the Edman degradation analysis performed in this study. Since modifications are frequent in deposited proteins, the 50-kDa AMY seen in AD brain may represent a posttranslationally truncated form of the 70-kDa variant secreted from cells. The 100-kDa AMY could then correspond to an FA-and SDS-stable dimer of the 50-kDa AMY, although we did not address this issue in the present study.
The epitope of the AMY155 antibody was characterized by analyzing lysates from cells transfected with Cterminally truncated CLAC-P constructs. The AMY155 epitope was found to be located within collagen domain 2 (COL2), somewhere between amino acid residues 311-358. Thus, the AMY fragment shown by immunohistochemistry to be co-deposited with A␤ extends beyond residue 311. The amino acid sequence between residues 311-358 shows some homology to collagen XIII. However, no cross-reactivity with recombinantly expressed collagen XIII was seen with either AMY155 or AMY117 (data not shown). It is interesting to note that no AMY immunoreactivity can be found colocalizing with A␤ plaques in monkeys or APP transgenic mice (18) , although in the latter case there is 100% sequence identity between human and murine CLAC in the 311-358 region.
A number of proteins have been suggested to be associated with A␤ in AD plaques (9) and it has been hypothesized that these proteins influence pathogenic A␤ deposition in AD brain. The processes underlying the transition of soluble A␤ into the highly ordered aggregates in brain are undoubtedly complex, and although A␤ spontaneously forms fibrils in vitro, other proteins may enhance this assembly in vivo. For many of the proteins suggested to co-deposit with A␤ in plaques, the supporting evidence is based mainly on data obtained from immunohistochemical investigations (9) . Notable exceptions are apoE and ␣ 1 -antichymotrypsin, where there is substantial evidence from in vivo studies in mice confirming an important role for both molecules in determining plaque density (13, 14, 24) . Conflicting views exist as to whether apoE and ␣ 1 -antichymotrypsin initiates A␤ deposition or attenuates of A␤ clearance.
AMY fulfills 2 criteria for being a true AD amyloidassociated protein: colocalization with A␤ by immunohistochemistry and co-purification with A␤ in SDS-resistant fractions from AD brain. In contrast to what has previously been shown for A␤ and a C-terminal fragment of apoE (21), A␤ does not appear to be bound directly to AMY in AD brain isolates. However, such complexes may exist, but due to their insolubility they are able to escape detection using the methods described here. In the study describing the identification of CLAC as a novel plaque component (19) , Northern blot analysis suggested a strict brain-specific expression. An appealing hypothesis may therefore be that AMY is a major co-factor that determines A␤ deposition in brain. However, it remains unclear why AMY exclusively associates with mature, neuritic plaques and why AMY staining is not seen in proximity to A␤ amyloid deposits in cerebral vessels.
Why is AMY co-deposited with A␤ in AD brain? Although very limited data are available on the interaction between AMY and A␤ in brain, AMY could possibly bind soluble A␤ and anchor the latter molecule to the extracellular matrix. Interestingly, AMY, like apoE, contains heparin-binding domains known to interact with heparan sulfate proteoglycans. Thus, AMY can serve as a molecular trap binding soluble and freely diffusible A␤ in the interstitial space. This bound A␤ could provide additional A␤-A␤ interaction sites and then serve as a nidus for further A␤ polymerization and deposition. Alternatively, AMY could bind to already deposited A␤ and inhibit or attenuate A␤ clearance. In this context, it is interesting to note that Hashimoto et al (19) reported that recombinant CLAC-P preferentially interacts with fibrillized A␤1-42. For either of these scenarios, perturbation of the AMY-A␤ interaction would be considered beneficial. Clearly, future studies aimed at understanding the temporal inter-relationship between AMY and A␤ co-deposition and probing of the respective interaction domains are warranted. Finally, we propose that the AMY protein hereafter is referred to as CLAC.
